BC
RARE icon

Burleson & Co’s Ultragenyx Pharmaceutical RARE Stock Holding History

Burleson & Co’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$463 Hold
10
– – ﹤0.01% 382
2022
Q3 		$0 Hold
10
– – ﹤0.01% 475
2022
Q2 		$1K Hold
10
– – ﹤0.01% 394
2022
Q1 		$1K Hold
10
– – ﹤0.01% 380
2021
Q4 		$1K Hold
10
– – ﹤0.01% 339
2021
Q3 		$1K Hold
10
– – ﹤0.01% 334
2021
Q2 		$1K Sell
10
-40
-80% -$4.17K ﹤0.01% 345
2021
Q1 		$6K Buy
+50
New +$6.81K ﹤0.01% 277

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Burleson & Co's RARE Position: Q4 2022 in Review

Burleson & Co held its Ultragenyx Pharmaceutical (RARE) position steady in Q4 2022 at 10 shares worth $463. The position accounts for ﹤0.01% of the portfolio, ranked #382.

Burleson & Co first reported a position in RARE in Q1 2021 and has held it in 8 quarters since. The position peaked at $6K in Q1 2021. 228 funds tracked by Wall St. Rank hold RARE as of Q4 2022.

  • Burleson & Co held 10 shares of Ultragenyx Pharmaceutical worth $463 as of Q4 2022.
  • Burleson & Co left its Ultragenyx Pharmaceutical share count unchanged in Q4 2022.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Burleson & Co's portfolio in Q4 2022, its #382 holding.
  • Burleson & Co first reported a position in Ultragenyx Pharmaceutical in Q1 2021 and has held it in 8 quarters since.
  • Burleson & Co's Ultragenyx Pharmaceutical position peaked at $6K in Q1 2021.
  • 228 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2022.

Based on Burleson & Co's 13F filing for Q4 2022, filed 31 Jan 2023.